Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 13138Neoplasms 10481Carcinoma, Non-Small-Cell Lung 6874Prostatic Neoplasms 6268Colorectal Neoplasms 5948Lung Neoplasms 5105Multiple Myeloma 3577Pancreatic Neoplasms 3563Leukemia, Myeloid, Acute 3510Neoplasm Metastasis 3508Carcinoma, Hepatocellular 3273Ovarian Neoplasms 3168Melanoma 3141Stomach Neoplasms 3057Lymphoma 2983Head and Neck Neoplasms 2604Recurrence 2557Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Colonic Neoplasms 2328Brain Neoplasms 2313Lymphoma, Non-Hodgkin 2269Rectal Neoplasms 2192Uterine Cervical Neoplasms 2191Glioblastoma 2016Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1913Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1848Esophageal Neoplasms 1801

Interventions

zirconium-89-trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Solid Tumor × Clear all
NCT04757090 2021-12-23

89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

Washington University School of Medicine

Phase 2 Withdrawn
Other solid neoplasm

HER2-positive Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡